1. The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside
- Author
-
Yukun Li, Rong Lin, Xiaodong Peng, Xuesi Wang, Xinmeng Liu, Linling Li, Rong Bai, Songnan Wen, Yanfei Ruan, Xing Chang, Ribo Tang, and Nian Liu
- Subjects
Aging ,Antibiotics, Antineoplastic ,Daunorubicin ,Cell Biology ,General Medicine ,Biochemistry ,Cardiotoxicity ,Mitochondria ,Mitochondrial Proteins ,Doxorubicin ,Humans ,Anthracyclines ,Calcium ,Myocytes, Cardiac ,Idarubicin ,Reactive Oxygen Species ,Epirubicin - Abstract
Cardiotoxicity is the major side effect of anthracyclines (doxorubicin, daunorubicin, epirubicin, and idarubicin), though being the most commonly used chemotherapy drugs and the mainstay of therapy in solid and hematological neoplasms. Advances in the field of cardio-oncology have expanded our understanding of the molecular mechanisms underlying anthracycline-induced cardiotoxicity (AIC). AIC has a complex pathogenesis that includes a variety of aspects such as oxidative stress, autophagy, and inflammation. Emerging evidence has strongly suggested that the loss of mitochondrial quality control (MQC) plays an important role in the progression of AIC. Mitochondria are vital organelles in the cardiomyocytes that serve as the key regulators of reactive oxygen species (ROS) production, energy metabolism, cell death, and calcium buffering. However, as mitochondria are susceptible to damage, the MQC system, including mitochondrial dynamics (fusion/fission), mitophagy, mitochondrial biogenesis, and mitochondrial protein quality control, appears to be crucial in maintaining mitochondrial homeostasis. In this review, we summarize current evidence on the role of MQC in the pathogenesis of AIC and highlight the therapeutic potential of restoring the cardiomyocyte MQC system in the prevention and intervention of AIC.
- Published
- 2022
- Full Text
- View/download PDF